Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000727518 | SCV000709390 | uncertain significance | not provided | 2017-06-16 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000594415 | SCV000729046 | likely benign | not specified | 2017-06-05 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Ambry Genetics | RCV002377239 | SCV002624833 | uncertain significance | Cardiovascular phenotype | 2020-01-09 | criteria provided, single submitter | clinical testing | The p.R13064C variant (also known as c.39190C>T), located in coding exon 142 of the TTN gene, results from a C to T substitution at nucleotide position 39190. The arginine at codon 13064 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV000727518 | SCV003819698 | uncertain significance | not provided | 2022-05-12 | criteria provided, single submitter | clinical testing |